Jinjin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinjin Wu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Guihong Yang
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China
2 shared publicationsHui Tang
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China
2 shared publicationsQiaoyu Xu
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China
2 shared publicationsShuqian Tang
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China
2 shared publicationsXiaokun Yang
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China; Department of Emergency, General Hospital of Chengdu Military Command Area, Chengdu 610083, Sichuan Province, PR China
2 shared publicationsYadong Yang
Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing 400042, PR China
2 shared publications
Latest Publications
- Open Access
- 1 September 2015
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 129 (1) , 65-71
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model
- 1 September 2015
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 129 (1) , 65-71
Open AccessEphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model
- Open Access
- 1 January 2014
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 125 (3) , 255-263
Anti-tumor Effect of Polysaccharides From Scutellaria Barbata D. Don on the 95-D Xenograft Model via Inhibition of the C-Met Pathway
Polysaccharides isolated from Scutellaria barbata (PSB) have been reported to have anti-tumor effects. To investigate the underlying mechanism, a highly invasive, metastatic and phospho-c-Met overexpression lung carcinoma cell, 95-D cell line was used. The results showed that in vitro, PSB not only could inhibit the proliferation of 95-D cell line (IC50 = 35.2 μg/mL), but also down-regulated the expression of phospho-c-Met and its downstream signaling molecules including phospho-Erk and phospho-Akt. In vivo, PSB inhibited tumor growth in the 95-D subcutaneous xenograft model in a dose-dependent manner; after once-daily intraperitoneal injection for 3 weeks, tumor growth inhibition T/C ratio for 100 and 200 mg/kg treatments was 42.72% and 13.6%, respectively. In the end of the in vivo study, tumor tissues were harvested for further evaluation of the phosphorylation level of c-Met, AKT, and ERK. Ex vivo results demonstrated that the phosphorylation of c-Met and its downstream signaling molecules were also significantly inhibited by PSB. Immunohistochemistry analysis showed dose-dependent inhibition of tumor cell proliferation (Ki67) and reduction of microvessel density (CD31). In summary, the results indicated that PSB exerted anti-tumor growth activity on human lung cancer 95-D in vitro and in vivo by directly regulating the c-Met signaling pathway and the anti-tumor effects were mainly based on its anti-proliferation and anti-angiogenesis action.
- 1 January 2014
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 125 (3) , 255-263
Open AccessAnti-tumor Effect of Polysaccharides From Scutellaria Barbata D. Don on the 95-D Xenograft Model via Inhibition of the C-Met Pathway
Polysaccharides isolated from Scutellaria barbata (PSB) have been reported to have anti-tumor effects. To investigate the underlying mechanism, a highly invasive, metastatic and phospho-c-Met overexpression lung carcinoma cell, 95-D cell line was used. The results showed that in vitro, PSB not only could inhibit the proliferation of 95-D cell line (IC50 = 35.2 μg/mL), but also down-regulated the expression of phospho-c-Met and its downstream signaling molecules including phospho-Erk and phospho-Akt. In vivo, PSB inhibited tumor growth in the 95-D subcutaneous xenograft model in a dose-dependent manner; after once-daily intraperitoneal injection for 3 weeks, tumor growth inhibition T/C ratio for 100 and 200 mg/kg treatments was 42.72% and 13.6%, respectively. In the end of the in vivo study, tumor tissues were harvested for further evaluation of the phosphorylation level of c-Met, AKT, and ERK. Ex vivo results demonstrated that the phosphorylation of c-Met and its downstream signaling molecules were also significantly inhibited by PSB. Immunohistochemistry analysis showed dose-dependent inhibition of tumor cell proliferation (Ki67) and reduction of microvessel density (CD31). In summary, the results indicated that PSB exerted anti-tumor growth activity on human lung cancer 95-D in vitro and in vivo by directly regulating the c-Met signaling pathway and the anti-tumor effects were mainly based on its anti-proliferation and anti-angiogenesis action.